CRYOPORT, INC. Repayments of Senior Debt
CRYOPORT, INC. (CYRX) reported Repayments of Senior Debt of $163.77 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSeniorDebt · last filed 2025-03-07
- CRYOPORT, INC. repayments of senior debt for the quarter ending 2024-12-31 was $0.00.
- CRYOPORT, INC. repayments of senior debt for the quarter ending 2024-09-30 was $155.11M.
- CRYOPORT, INC. repayments of senior debt for the quarter ending 2023-12-31 was $0.00.
- CRYOPORT, INC. repayments of senior debt for fiscal 2024 was $163.77M, a 555.01% increase from fiscal 2023.
- CRYOPORT, INC. repayments of senior debt for fiscal 2023 was $25.00M.
| Period end | Repayments of Senior Debt 3 month | Repayments of Senior Debt 6 month | Repayments of Senior Debt 9 month | Repayments of Senior Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $155.11M derived: sum of 2 quarters · filed 2025-03-07 | $163.77M 10-K · filed 2025-03-07 | |
| 2024-09-30 | $155.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $163.77M 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $8.66M 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $25.00M 10-K · filed 2025-03-07 | ||
| 2023-09-30 | $25.00M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |